Doximity (NYSE:DOCS) is one of the most promising mid-cap healthcare stocks under $50.
On December 16, Bank of America analyst Allen Lutz reiterated his bullish stance on Doximity (NYSE:DOCS). He assigned a Buy rating to the stock with a $82 price target. This implies a highly attractive 88% upside potential for investors within the prevailing trading range.
Lutz attributed such upside to accelerating growth within the healthcare provider (HCP) budgets, as Doximity (NYSE:DOCS) has also been raising its budgetary allocation towards HCP advertising. He noted that such a shift towards HCP comes on the back of meager growth within direct-to-consumer (DTC) advertising. Another area of focus for Doximity (NYSE:DOCS) is the digital video initiatives, which are also a growth catalyst, as per experts.
As of December 19 closing, the consensus estimates reflect a positive analyst sentiment for Doximity (NYSE:DOCS), after the stock has dropped more than 18% in 2025. Of the 15 analyst ratings assigned to the stock, 8 were Buy calls, 5 were Hold calls, and only 2 were Sell calls. Analysts forecast a 1-year average price target of $66.62 per share, implying 52.6% upside from the current level.
Doximity (NYSE:DOCS) is a digital platform that provides online networking services for healthcare and medical professionals. The company has an extensive network currently covering around 80% of U.S.-based physicians. Their AI-powered application helps in efficient HIPAA-compliant communication among healthcare professionals.
While we acknowledge the potential of DOCS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT:  Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.
Disclosure: None. This article is originally published at Insider Monkey.
